ArticleJournal of biomedical physics & engineering2020
Comparing Lymphocyte Radiosensitivity of Prostate Cancer Patients with Healthy Donors Using Micronuclei and Chemical Premature Chromosome Condensation Tests.
Article in Journal of biomedical physics & engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytogenetic tests are usually used for diagnosing predisposed individuals to cancer by determining their lymphocyte radiosensitivity.
objectiveTo determine the potential role of radiosensitivity in predisposition of prostate cancer by comparing lymphocyte radiosensitivity of prostate cancer patients with healthy donors. MATERIALS AND
methodsIn this experimental study, the blood samples of 10 prostate cancer patients and 10 healthy donors were irradiated to 0.25, 0.5, 1, 2, 4 and 6 Gy ionizing radiation produced by a 6MV Linac. One sample of each group receiving no radiation was regarded as the background. The micronuclei (MN) and chemical premature chromosome condensation (PCC) cytogenetic tests were performed on all samples and the numbers of MN and PCC rings were scored. Dose-response curves were plotted for both healthy and cancerous groups with two tests.
resultsThere was a significant difference between the numbers of MN within each group due to different levels of radiation doses. There was also a significant difference between the two groups in all identical doses, with the exception of 6 Gy. The chemical PCC test indicated a significant difference between the scored PCC rings in each group at doses higher than 0.25 Gy. However, no differences were noted between the healthy donors and prostate cancer patients receiving the same level of doses.
conclusionMN test can be considered as a reliable indicator of predisposition of prostate cancer. On the other hand, the chemical PCC test could not differentiate between healthy donors and prostate cancer patients at the dose range examined in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.